Central Drugs Standard Control Organization flags quality lapses in routine surveillance, with NSQ and spurious medicines under investigation to protect patient safety.
CDSCO mandates batch-wise NDMA testing in ranitidine, urges expiry cuts, storage reviews, and launches expert study amid cancer risk concerns linked to the antacid's long-term safety.